Clinical Trial

A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin/Pioglitazone combination therapy
Trial Details
NCT Number NCT06649162
Lead Sponsor Boryung Pharmaceutical Co., Ltd
Conditions Type 2 Diabetes
Enrollment 10,000 participants
Start Date 2024-09-30
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2024-10-18